Greater baseline tumor proliferation, as reflected in Ki-67 positivity, has previously been associated with higher pCR rates across breast cancer subtypes, but its prognostic significance in the neoadjuvant setting may be dependent not only on subtype but also on pCR status39. This evidence concerns the gene MKI67 and breast carcinoma.